A single administration of the new lithium compound with prolonged action formed on the basis of lithium oxyburate produces an antiblepharoptosis effect in rats with reserpine depression for 24 to 48 h. It optimally prevents the development of "reserpine-desynchronization" in rats when prescribed in the morning at intervals of 48 h.